Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually

Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually

Sep 22, 2020 | News

Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually Scott Wooldridge | BenefitsPro “The report, from Matrix Global Advisors and the Coalition for Affordable Prescription Drugs (CAPD), looked at five prescription drugs:...
Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says

Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says

Sep 15, 2020 | News

Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says Maia Anderson | Becker’s Hospital Review “An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S....
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year

New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year

Sep 14, 2020 | Press Releases

New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year Alex Brill | Washington, DC Today, Matrix Global Advisors (MGA) released a new report, “The Cost of Brand Drug Product Hopping,” commissioned by the Coalition for...
  • Analysis (38)
  • Books (3)
  • Events (15)
  • Interviews (48)
  • News (51)
  • Op-Eds (80)
  • Press Releases (4)
  • Testimony (20)
  • Health Care Workforce Shortages
    Health Care Workforce Shortages: An Updated LookFebruary 21, 2023
  • New MGA Analysis of the Adalimumab Biosimilars Market in the United StatesFebruary 21, 2023
  • Squawk Box tax policy
    MGA’s Alex Brill on CNBC’s Squawk Box Discussing the Recent Tax Policy ProposalFebruary 13, 2023
  • Curb Drug Patent Abuse
    Bipartisan Senate Bill Aims to Curb Drug Patent AbuseFebruary 1, 2023
  • Humira rivals drive down cost
    Humira Rivals Set to Try to Drive Down Cost of Blockbuster DrugJanuary 31, 2023
  • patent thickets lost drug savings
    New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent ThicketsJanuary 26, 2023
  • Biosimilar Coverage in Commercial
    New MGA Analysis of Biosimilar Coverage in Commercial Medical BenefitDecember 8, 2022
  • Narrow House GOP Victory
    Narrow House GOP Victory Should Point Toward Policy Development AgendaDecember 6, 2022
  • Health Care Workforce Shortages
    Don’t Let Pandemic Fatigue Inhibit Pandemic PreparednessNovember 15, 2022
  • Pro-Growth Tax System.
    American Renewal: A Simpler, More Responsible, and Pro-Growth Tax SystemNovember 15, 2022
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact